2-氯-4-甲基苯胺 | 51085-51-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-甲基苯胺
• 英文名称: 4-methyl-2-chloroaniline hydrochloride
• 英文别名: 2-chloro-4-methyl-aniline; hydrochloride；2-Chlor-4-methyl-anilin; Hydrochlorid；2-Chloro-4-methylaniline hydrochloride；2-chloro-4-methylaniline;hydrochloride
• CAS: 51085-51-9
• 化学式: C₇H₈ClN*ClH
• 分子量: 178.061
• InChiKey: VIKKIUPTGXMFDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921430090

反应信息

• 作为反应物：
  描述：

  2-氯-4-甲基苯胺 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 水 、 silver nitrate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氯化碳 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 为溶剂， 反应 53.0h， 生成 N-[4-(daunorubicin-N-carbonyloxymethyl)-2-chlorophenyl] O-(methyl 2,3,4-tri-O-acetyl-β-D-glucopyranuronosyl) carbamate
  参考文献：
  名称：

  Novel anthracycline-spacer-β-glucuronide, -β-glucoside, and -β-galactoside prodrugs for application in selective chemotherapy

  摘要：

  A series of anthracycline prodrugs containing an immolative spacer was synthesized for application in selective chemotherapy. The prodrugs having the general structure anthracycline-spacer-beta-glycoside were designed to be activated by beta-glucuronidase or beta-galactosidase. Prodrugs with -chloro, bromo or -n-hexyl substituents on the spacer were synthesized as well as prodrugs containing a -beta-glucuronyl, -beta-glucosyl or -beta-galactosyl carbamate specifier. The key step in the synthesis of all prodrugs is the highly beta-diastereoselective addition reaction of the anomeric hydroxyl of a glycosyl donor to a spacer isocyanate resulting in the respective beta-glycosyl carbamate pro-moieties. The resulting protected pro-moieties were coupled to an anthracycline. Prodrugs were evaluated with respect to activation rate by the appropriate enzyme and additionally, their IC50 values were determined. Optimal prodrugs in this study were at least 100- to 200-fold less toxic than their corresponding drug in vitro and were activated to the parent drug in a half-life time of approximately 2 h. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00095-4

文献信息

• Pesticidal compositions
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0347227A1

  公开（公告）日：1989-12-20

  A palatable pesticidal composition in solid form comprising, based on the total composition, (a) 0.5 to 33 weight % of ethylene/vinyl acetate copolymer with from 18 to 50 weight % vinyl acetate, (b) an effective amount of a bioactive agent, and (c) a protein/carbohydrate/lipid source providing the remaining weight.

  一种固体形式的适口杀虫组合物，以组合物总量为基准，包括 (a) 0.5 至 33 重量百分比的乙烯/醋酸乙烯共聚物，其中醋酸乙烯占 18 至 50 重量百分比、 (b) 有效量的生物活性剂，以及 (c) 提供剩余重量的蛋白质/碳水化合物/脂质来源。
• CH594614
  申请人：——

  公开号：——

  公开（公告）日：——
• NIELSEN, F. E.;NIELSEN, K. E.;PEDERSEN, E. B., CHEM. SCR., 1984, 24, N 4-5, 208-223
  作者：NIELSEN, F. E.、NIELSEN, K. E.、PEDERSEN, E. B.

  DOI：——

  日期：——
• US5135744A
  申请人：——

  公开号：US5135744A

  公开（公告）日：1992-08-04
• Novel anthracycline-spacer-β-glucuronide, -β-glucoside, and -β-galactoside prodrugs for application in selective chemotherapy
  作者：Ruben G.G. Leenders、Eric W.P. Damen、Edward J.A. Bijsterveld、Hans W. Scheeren、Pieter H.J. Houba、Ida H. van der Meulen-Muileman、Epie Boven、Hidde J. Haisma

  DOI：10.1016/s0968-0896(99)00095-4

  日期：1999.8

  A series of anthracycline prodrugs containing an immolative spacer was synthesized for application in selective chemotherapy. The prodrugs having the general structure anthracycline-spacer-beta-glycoside were designed to be activated by beta-glucuronidase or beta-galactosidase. Prodrugs with -chloro, bromo or -n-hexyl substituents on the spacer were synthesized as well as prodrugs containing a -beta-glucuronyl, -beta-glucosyl or -beta-galactosyl carbamate specifier. The key step in the synthesis of all prodrugs is the highly beta-diastereoselective addition reaction of the anomeric hydroxyl of a glycosyl donor to a spacer isocyanate resulting in the respective beta-glycosyl carbamate pro-moieties. The resulting protected pro-moieties were coupled to an anthracycline. Prodrugs were evaluated with respect to activation rate by the appropriate enzyme and additionally, their IC50 values were determined. Optimal prodrugs in this study were at least 100- to 200-fold less toxic than their corresponding drug in vitro and were activated to the parent drug in a half-life time of approximately 2 h. (C) 1999 Elsevier Science Ltd. All rights reserved.